10-Q: AirSculpt Technologies Reports Q2 Loss Amid Revenue Decline, Initiates Strategic Turnaround and Debt Reduction

AirSculpt Technologies experienced significant revenue and case volume declines in the second quarter of 2025, leading to a net loss, but is implementing strategic initiatives and has raised capital to stabilize performance and reduce debt.

Summary

• Revenue for the three months ended June 30, 2025, decreased by 13.7% to $44.012 million, down from $51.004 million in the same period of 2024.
• Revenue for the six months ended June 30, 2025, decreased by 15.5% to $83.383 million, down from $98.624 million in the same period of 2024.
• Net loss for the three months ended June 30, 2025, was $0.591 million, an improvement from a net loss of $3.206 million in the prior year period.
• Net loss for the six months ended June 30, 2025, was $3.438 million, compared to a net income of $2.823 million in the prior year period.
• Cases performed declined by 14.1% for the three months and 15.9% for the six months ended June 30, 2025, compared to the respective prior year periods.
• Revenue per case slightly increased by 0.5% to $12,975 for the three months and 0.6% to $12,892 for the six months ended June 30, 2025.
• Adjusted EBITDA for the three months ended June 30, 2025, was $5.835 million, down from $6.868 million in the prior year period.
• Adjusted EBITDA for the six months ended June 30, 2025, was $9.590 million, down from $14.205 million in the prior year period.
• Selling, general and administrative expenses decreased by $11.6 million (33.9%) for the three months and $5.6 million (11.2%) for the six months ended June 30, 2025, primarily due to reduced advertising, lower stock compensation expense, and decreased severance costs.
• A cost reduction program has been implemented, estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses.
• The company completed an underwritten public offering on June 11, 2025, raising net proceeds of approximately $13.8 million from the sale of 3,634,000 shares at $3.80 per share.
• An At-the-Market (ATM) common offering program was initiated on March 14, 2025, allowing for the sale of up to $50.0 million in common stock; approximately $264 thousand in net proceeds were raised through this program for the six months ended June 30, 2025.
• A $10.0 million principal payment was made on the term loan on June 13, 2025, using proceeds from the underwritten public offering.
• Total debt, net, decreased to $57.738 million as of June 30, 2025, from $69.706 million as of December 31, 2024.
• Cash and cash equivalents were $8.189 million as of June 30, 2025, with $5.0 million available on the revolving credit facility.

Sentiment

Score: 3

Explanation: The company experienced significant revenue and case volume declines, leading to a net loss for the six-month period. While management is implementing strategic initiatives and has successfully raised capital to address liquidity and debt, the current financial performance indicates substantial headwinds and a challenging operating environment.

Positives

• Net loss for the three months ended June 30, 2025, significantly improved to $0.591 million from $3.206 million in the prior year.
• Selling, general and administrative expenses decreased substantially due to reductions in advertising, stock compensation, and severance costs.
• The company successfully completed an underwritten public offering, raising $13.8 million in net proceeds.
• A $10.0 million principal payment was made on the term loan, reducing outstanding indebtedness.
• A cost reduction program is in place, expected to save $3.0 million in annual overhead costs.
• Revenue per case slightly increased for both the three and six-month periods, indicating stable pricing per procedure.

Negatives

• Revenue declined by 13.7% for the three months and 15.5% for the six months ended June 30, 2025, compared to the prior year periods.
• Case volumes decreased by 14.1% for the three months and 15.9% for the six months ended June 30, 2025.
• The company reported a net loss of $3.438 million for the six months ended June 30, 2025, a reversal from a net income of $2.823 million in the prior year.
• Adjusted EBITDA decreased for both the three and six-month periods, reflecting reduced profitability from operations.
• Cost of service as a percentage of revenue increased due to the inability to leverage certain fixed costs amidst declining revenue.
• The company's working capital remained a deficit of $(9.4) million as of June 30, 2025.

Risks

• Inability to sell equity or other securities in the future at a time when sales might be desired.
• Inability to raise capital on commercially reasonable terms, if at all, with potential for future financings to dilute stockholders or restrict business.
• Failure to stabilize same-center performance, which has seen significant declines.
• Inability to optimize marketing investment, go-to-market strategy, and sales processes.
• Lack of ability to expand financing options for consumers.
• Unsuccessful future product innovations.
• Failure to operate centers in a cost-effective manner.
• Increased operating expenses due to rising inflation.
• Increased competition in the weight loss and obesity solutions market, including from weight-loss drugs.
• Shortages or quality control issues with third-party manufacturers or suppliers.
• Competition for surgeons.
• Litigation or medical malpractice claims.
• Inability to protect the confidentiality of proprietary information.
• Changes in laws governing the corporate practice of medicine or fee-splitting.
• Changes in regulatory, macroeconomic conditions, including inflation and the threat of recession.
• Business disruption or other losses from natural disasters, war, pandemic, terrorist acts, or political unrest.

Future Outlook

The company aims to stabilize revenue growth through several strategic priorities, including optimizing marketing investment with a returns-based approach and testing new online video and social marketing channels under a new Chief Digital Officer. It plans to improve go-to-market and sales strategies with enhanced training and focus on lead generation, consultations, and case conversion under a new Chief Sales Officer. Initiatives to enhance customer experience are in development for rollout in the second half of fiscal year 2025 and into fiscal year 2026. Expanded consumer financing options are being launched across all centers in the first half of fiscal year 2025, and new product innovation, including expanding a skin tightening procedure pilot, is a focus to leverage existing infrastructure and generate incremental revenues. A cost reduction program is expected to eliminate approximately $3.0 million in annual overhead costs, and de novo center and new procedure room openings have been paused.

Management Comments

• The decrease in revenue is primarily attributed to weaker than expected performance across the broader aesthetics industry and high-end retail industries.
• We have implemented a cost reduction program that is estimated to eliminate approximately $3.0 million in annual overhead costs and contracted expenses.
• We have also paused de novo center and new procedure room openings.
• We believe that the cash expected to be generated from operations will be sufficient for our working capital requirements, liquidity obligations, and payments due under our existing credit facilities for at least the next 12 months.

Industry Context

The company's performance is significantly impacted by a weaker than expected trend across the broader aesthetics industry and high-end retail sectors. This suggests a challenging market environment for discretionary medical procedures, potentially influenced by broader macroeconomic conditions or increased competition, including from the growing market acceptance of weight-loss drugs.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing to assess performance against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in pending and threatened legal actions and proceedings, mostly related to medical malpractice claims, which are considered ordinary course of business and not expected to have a material adverse effect on financial condition, results of operations, or cash flows. Insurance coverage is maintained for these claims.

Related Party Transactions

• Vesey Street Capital Partners, L.L.C., the company's private equity sponsor and largest stockholder, purchased an aggregate of 1,000,000 shares in the underwritten public offering on the same terms as public purchases.
• Vesey Street Capital Partners, L.L.C. (through affiliated entities) provided a $10.0 million limited guarantee of the company's obligations under the Credit Agreement, callable on June 15, 2025, if a $10.0 million term loan prepayment was not made.

Stakeholder Impact

• Shareholders: Experienced dilution from the public offering and ATM program, but the capital raise helped reduce debt and improve liquidity. Continued net losses and revenue decline may negatively impact share price.
• Employees: Subject to a cost reduction program estimated to eliminate $3.0 million in annual overhead costs, which could imply job reductions or reduced benefits.
• Customers: May benefit from expanded consumer financing options and new product innovations like the skin tightening procedure, potentially enhancing accessibility and service offerings.
• Creditors: The Credit Agreement amendment and debt prepayment from equity proceeds improve the company's debt profile and compliance with covenants, reducing immediate credit risk.

Next Steps

• Optimize marketing investment using a returns-based approach and testing new online video and social marketing channels.
• Improve go-to-market and sales strategies with enhanced training and focus on increasing lead generation, consultations, and case conversion.
• Roll out initiatives to enhance customer experience in the second half of fiscal year 2025 and into fiscal year 2026.
• Launch expanded consumer financing offerings across all centers in the first half of fiscal year 2025.
• Focus on new product innovation and introducing new services, including expanding the pilot program of skin tightening as a standalone offering.
• Continue with the cost reduction program to eliminate approximately $3.0 million in annual overhead costs.
• Annual review of goodwill impairment will be performed in October 2025.
• Evaluate the provisions and potential effects of the One Big Beautiful Bill Act (OBBBA) on financial statements.

Key Dates

Recommendation

The company faces significant operational headwinds, evidenced by declining revenue and case volumes, and a shift from net income to net loss for the six-month period. While management is actively addressing these challenges through strategic initiatives, cost reductions, and a successful capital raise to reduce debt, the turnaround is in its early stages. The market for aesthetic procedures is also noted as weaker. A 'hold' recommendation is appropriate for investors who are willing to wait and see if the strategic adjustments yield positive results and if the broader industry conditions improve, but the current financial performance does not warrant a 'buy' given the uncertainties.

Keywords

AirSculpt, Body Contouring, Minimally Invasive Liposuction, Aesthetics Industry, SEC Filing, 10-Q, Financial Results, Revenue, Net Loss, Adjusted EBITDA, Capital Raise, Debt Reduction, Strategic Initiatives, Medical Procedures, Cosmetic Surgery